NEW YORK and MAINZ, GERMANY, November 4, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (BNTX) (Nasdaq: BNTX) today announced updated data from a Phase 2/3 clinical trial demonstrating a robust ...

Video above: FDA votes to authorize more COVID-19 boosters, mix-and-matching doses in some casesA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — ...

We investigated county-level variation in mRNA COVID-19 vaccine use among Medicare beneficiaries throughout the United States. There was greater use of Pfizer-BioNTech vaccines than Moderna vaccines ...

Pfizer and BioNTech said Friday that the immune responses against Omicron BA.4/BA.5 subvariants were "substantially higher" in people who got its new bivalent booster compared with people who received ...

Nearly two years since the original coronavirus vaccines were given emergency authorization for use, we now have an updated vaccine that can be given as a booster shot. Here’s what we currently know ...

Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) is FDA-authorized under Emergency Use Authorization (EUA) for use in individuals 12 years of age and older as a single ...

BioNTech reported EUR 6.1 billion in revenue and EUR 3.2 billion in net profit in the third quarter, driven by BioNTech and partner Pfizer's sales of COVID-19 vaccine Comirnaty, and we're maintaining ...

Ducharme is a contributor to TIME. A health worker in Chile vaccinates someone with an AstraZeneca shot as a third booster dose against COVID-19 on Aug. 10, 2021. Ducharme is a contributor to TIME.

(Reuters) – Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus. They are ...

The US Food and Drug Administration on Thursday authorized the Pfizer/BioNTech Covid-19 vaccine for use as a booster in people ages 16 and 17. It's the first Covid-19 vaccine booster authorized for ...

Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust immune responses The booster dose ...